Fractyl Health Posts 62% Wider Q2 Loss
Fractyl Health (NASDAQ:GUTS), a clinical-stage biotech developing interventions for obesity and Type 2 Diabetes (T2D), reported its second quarter 2025 results on August 12, 2025. The period was marked by no recognized revenue, a net loss of $27.9 million, and continued progress in late-stage clinical programs, particularly the Revita platform for post-GLP-1 weight maintenance. Matching the expectation of no reported revenue and an estimated EPS loss of $0.36. Relative to previous periods, research and development expenses increased, while Selling, general, and administrative costs dropped to $4.9 million from $6.2 million in Q2 2024. Management described the quarter as one of major clinical acceleration but noted ongoing operating losses and cash burn typical for a company at this stage.
Source: Analyst estimates for the quarter provided by FactSet.
Fractyl Health specializes in disease-modifying therapies for obesity and T2D. Its aim is to address underlying causes of these conditions rather than just manage symptoms. The company's approach includes the Revita Duodenal Mucosal Resurfacing (DMR) system, an endoscopic procedure targeting gut hormone changes that influence metabolic health, and the Rejuva gene therapy platform focused on long-term metabolic disease remission.
Source Fool.com
